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Abstract
Background
Mutations in the cystic fibrosis transmembrane regulator (CFTR) gene can reduce function
of the CFTR ion channel activity and impair cellular chloride secretion. The gold standard
method to assess CFTR function of ion transport using the Ussing chamber requires a high
number of airway epithelial cells grown at air-liquid interface, limiting the application of this
method for high throughput screening of potential therapeutic compounds in primary airway
epithelial cells (pAECs) featuring less common CFTR mutations. This study assessed an
alternative approach, using a small scale halide assay that can be adapted for a personal-
ized high throughput setting to analyze CFTR function of pAEC.
Methods
Pediatric pAECs derived from children with CF (pAECCF) were established and expanded
as monolayer cultures, before seeding into 96-well plates for the halide assay. Cells were
then transduced with an adenoviral construct containing yellow fluorescent protein (eYFP)
reporter gene, alone or in combination with either wild-type CFTR (WT-CFTR) or p.Phe508-
del CFTR. Four days post transduction, cells were stimulated with forskolin and genistein,
and assessed for quenching of the eYFP signal following injection of iodide solution into the
assay media.
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Results
Data showed that pAECCF can express eYFP at high efficiency following transduction with
the eYFP construct. The halide assay was able to discriminate functional restoration of
CFTR in pAECCF treated with either WT-CFTR construct or the positive controls syntaxin 8
and B-cell receptor-associated protein 31 shRNAs.
Significance
The current study demonstrates that the halide assay can be adapted for pediatric pAECCF
to evaluate restoration of CFTR function. With the ongoing development of small molecules
to modulate the folding and/or activity of various mutated CFTR proteins, this halide assay
presents a small-scale personalized screening platform that could assess therapeutic
potential of molecules across a broad range of CFTR mutations.
Introduction
Cystic fibrosis (CF) manifests as a multi-organ disease, however, lung disease presenting with
recurrent infections, chronic neutrophilic inflammation and structural pathologies remain the
primary cause of mortality [1,2]. The molecular basis of CF is a functionally defective ion chan-
nel, caused by inheritable mutations in the cystic fibrosis transmembrane conductance regula-
tor (CFTR) gene. Though more than 1000 mutations have been identified [1], the most
common mutation is a codon deletion in exon 10 for phenylalanine at position 508 (p.Phe508-
del) in the encoded CFTR polypeptide [3]. This leads to defective trafficking of the mutant pro-
tein to the cell membrane and also compromises the transport of chloride ions [4]. More than
90% of patients with CF have at least one p.Phe508del allele [5] and individuals bearing this
mutation are often associated with more severe phenotype [3].
In the lung, the CFTR protein is highly expressed at the apical surface of epithelial cells in
the airways [6] and its primary function is to help regulate the airway liquid microenviron-
ment through secretion of chloride ions and other molecules. However, defective function in
CF airways leads to a significantly altered airway environment, characterized by insufficient
mucociliary clearance that is further complicated by the secondary effects of recurrent,
destructive infections [2]. Airway epithelial cells (AECs) have been identified as highly relevant
targets for correction of CFTR function. However, development of potential therapeutics relies
on functional assays to quantify their effect on CFTR. The current gold standard method of
using Ussing chamber to measure ion transport through electrophysiology requires a high
number of AECs for each permeable insert grown at air-liquid interface (ALI), which pre-
cludes the use of primary AEC (pAEC) from pediatric CF populations. With the discovery that
small molecules can have the potential to actively correct CFTR and many more that are cur-
rently in the pipeline especially for rare mutations of CFTR, a small scale high-throughput
screening (HTS) platform is necessary to help realize personalized medicine approaches in
early CF. One such approach would be to adapt a halide sensitive fluorescent reporter mole-
cule for expression in pAEC and its utilization in an assay that assesses ion channel activity.
Verkman and colleagues [7] first reported measuring chloride concentrations via fluores-
cent indicators based upon heterocyclic organic compounds with quaternary nitrogen
like quinolinium. Follow-up studies investigated quinolinium salt-based halide sensitive
fluorescent probes such as (6-methoxy-N-9-sulphopropyl)quinolinium (SPQ) and
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N-(ethoxycarbonylmethyl)-6-methoxyquinolinium bromide (MQAE) [8,9], before green fluo-
rescent protein (GFP) was modified into a halide-sensitive indicator that measure chloride
transport in epithelial cells [10,11].
Many studies have assessed CFTR restoration using transformed cell lines and animal mod-
els [12–14], however, applying these investigations to freshly isolated primary cell populations
that better reflect natural biological variety poses some new and unique challenges. There have
only been three reports examining correction of p.Phe508del expression and function in
pAEC cultures [15–17] and all were conducted using adult-derived cells. Since pediatric popu-
lations present the ideal opportunity for early intervention, the aim of the present study was to
investigate whether functional restoration of p.Phe508del CFTR could be efficiently assessed
in pediatric-derived cystic fibrosis airway epithelial cells (pAECCF) using an adapted adenovi-
ral-based halide assay.
Materials and methods
Reagents
Bronchial Epithelium Basal Media (BEBM1) was purchased from Lonza (Clonetics1, Walk-
ersville, MD, USA); bovine pituitary extract, bovine serum albumin, fibronectin, hydrocorti-
sone, recombinant human epidermal growth factor, epinephrine hydrochloride, transferrin,
triiodothyronine, insulin, and retinoic acid were obtained from Sigma-Aldrich Pty. Ltd.
(St. Louis, MO, USA); trypsin/EDTA, penicillin/streptomycin, gentamycin, and fungizone
from Life Technologies Pty. Ltd (Melbourne, Australia); bovine collagen Type I from Becton
Dickinson Pty. Ltd (Bedford, MA, USA); synthetic serum Ultroser G acquired from Ciphergen
(Cergy-Saint-Christophe, France).
Subjects
For this study, 16 children with CF (7 male and 9 female children)under 7 years of age were
recruited when they came to hospital for their annual early surveillance visit [18]. This study
was approved by the Human Ethics Committee of Princess Margaret Hospital (1762/EP) and
written consent was obtained from the parents or legal guardians of each participant after
being fully informed about the nature and purpose of this study. Detailed characteristics of
donor subjects are provided in Table 1.
Establishment of pAECCF cultures
The pAEC were collected via brushing of the tracheal mucosa as previously described [19–21].
Brushes were collected and transported back to the laboratory on ice in media consisting of
RPMI-1640 [19,21]. Cells were then detached from the cytology brush tips by vortexing and
subsequent centrifugation at 500 g for 7 minutes at 4˚C. The resulting cell pellet was then resus-
pended in complete growth medium of BEBM supplemented with bovine pituitary extract
(50 μg/ml), hydrocortisone (0.5 μg/ml), epidermal growth factor (0.5 ng/ml), epinephrine
(0.5 μg/ml), triiodothyronine (6.5 ng/ml), insulin (5 μg/ml), transferrin (10 μg/ml), fungizone
(2.5 μg/ml), penicillin/streptomycin (100 Units/ml penicillin and 0.1 mg/ml streptomycin) and
gentamycin (50 μg/ml). Macrophages were removed via incubating cell solution on a dish
coated with anti-CD68 antibody. Following cell count, pAEC were seeded for culture establish-
ment into new flasks pre-coated with a solution of 10mM fibronectin, 30mM collagen and
100mM bovine serum albumin. Epithelial lineage of established pAEC cultures has been previ-
ously confirmed [19] with positive immunocytochemical staining for cytokeratin 19 (CK19;
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epithelial marker) and negative staining for vimentin (mesenchymal marker), CD1a (dendritic)
and von Willebrand factor (endothelial marker).
pAECCF culture maintenance
Established submerged monolayer cultures were maintained by feeding every second day with
fresh complete growth media and once confluent, cells were passaged by incubating them in
0.25% Trypsin/0.05% EDTA for 7 minutes at 37˚C. Cells were pelleted via centrifugation (500g
for 7 minutes at 4˚C) and were subsequently seeded in new culture flasks in complete growth
media. Cultures were further expanded as necessary once reaching 100% confluence. Follow-
ing expansion from the initial culture, cells were then utilized for halide assay at passage 2.
Here, cells were plated at density of 20,000 cells per well in 96-well black microplates (Greiner
Bio-One, Frickenhausen, Germany) and incubated for an additional 48 hours in complete
growth media prior to commencing the assay. Cells were seeded typically in triplicate wells for
each of the parameters tested.
Adenoviral vectors
To efficiently express a halide-sensitive enhanced yellow fluorescent protein (eYFP) in pAEC,
cDNA was expressed from adenovirus deleted for adenoviral genes E1 and E2A with adenovi-
ral type Ad5. The cDNA for p.Phe508del CFTR and wild type CFTR (WT-CFTR), as well as
short hairpin RNAs (shRNAs) that inhibited syntaxin 8 (STX8) or B-cell receptor-associated
protein 31 (BCAP-31) RNA, were also cloned in the same adenoviral vector type Ad5. Adeno-
viral titres were determined by quantitative PCR and defined as adenoviral particles (VP)
accordingly.
pAECCF transduction efficiency and cytotoxicity
In order to ensure that our pAECCF could be efficiently transduced by adenoviral vectors, cells
cultured in 96-well black microplates to 90% confluence were transduced with the eYFP vector
at different multiplicities of infection (MOI) of 500, 1000 and 2000 viral particles per cell.
Table 1. Demographics and characteristic of the study population at the time of cell sampling.
ID Sex Age (years) Genotype Pulmonary infection (cfu/ml) IL-8 (pg/ml) Neutrophils (x103/ml)
1 M 4.1 p.Gly551Asp/p.Arg117His Mixed oral flora (107 cfu/ml) 220 43.71
2 M 0.2 p.Phe508del/p.Phe508del None 620 18.46
3 M 5.2 p.Phe508del/p.Phe508del None 1690 90.46
4 F 3.2 p.Phe508del/p.Phe508del None 50 6.65
5 F 1.3 p.Phe508del/p.Phe508del None 240 8.19
6 F 0.3 p.Phe508del/p.Phe508del None 290 39.60
7 F 6.2 p.Phe508del/p.Phe508del S. Aureus (105 cfu/ml), mixed oral flora (107 cfu/ml) 1060 37.10
8 F 5.2 Phe508del/unknown Mixed oral flora (106 cfu/ml) 440 64.91
9 F 3.0 p.Phe508del/p.Phe508del Mixed oral flora (103 cfu/ml) 2380 197.86
10 M 5.3 p.Phe508del/p.Phe508del Mixed oral flora (103 cfu/ml) 290 5.58
11 F 1.9 p.Phe508del/p.Phe508del N/A 800 91.61
12 M 5.1 p.Phe508del/p.Phe508del N/A 1170 21.1
13 F 5.1 p.Phe508del/p.Phe508del N/A 650 162.9
14 M 4.1 p.Phe508del/p.Gly551Asp N/A 1800 N/A
15 M 0.3 c.2052delA/p.Ser549Asn N/A 800 10.26
16 F 0.3 p.Phe508del/p.Arg117His N/A 100 31.53
https://doi.org/10.1371/journal.pone.0191618.t001
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Following incubation over 48–96 hours at 37˚C in a humidified atmosphere, eYFP fluores-
cence was imaged via fluorescence microscopy using 488 nm excitation and 525 nm emission
wavelengths. The eYFP-expressing cells were then quantified as a percentage of the total num-
ber of cells from 10 randomly chosen fields (containing > 100 cells) per sample. Positive cells
were then averaged over these 10 fields and then further averaged over triplicate images. Cell
cytotoxicity was determined by measuring the level of lactate dehydrogenase (LDH) using the
Cytotox 961 Non-radioactive cytotoxicity assay (Promega Corporation, Madison, WI, USA)
and performed as per manufacturer’s instructions. Cell viability following transduction was
also measured using the CellTiter 961 AQueous One Solution Cell Proliferation Assay (Pro-
mega) again according to the manufacturer’s instructions.
Optimization of halide reporter assay
To determine optimal output parameters, pAECCF were transduced with eYFP at MOI 500 for
96 hours and the fluorescent signal measured on a POLARStar fluorescent plate reader
(Optima BMG Lab Technologies, Germany). The plate reader was equipped with 485nm exci-
tation and HQ535/30M emission filters (Chroma Technology Corp., VT, USA), injectors to
deliver solution and ability to measure fluorescence from either top or bottom of the
microplate.
CFTR function analysis by halide reporter assay
Functional restoration of CFTR was assessed by the output readings of the halide reporter
assay as previously described [7,22]. Briefly, pAECCF were transduced with eYFP construct
alone or in combination with either WT-CFTR or p.Phe508del constructs for 96 hours at
37˚C. Cells were then washed in phosphate buffered saline (PBS) and incubated in gluconate
buffer containing 50 μM genistein and 10 μM forskolin for 5 minutes at room temperature to
stimulate CFTR activity. Next, the eYFP signal was detected using the POLARStar fluorescent
plate reader. After the initial 2 seconds reading, 110 μl of iodide solution (PBS modified with
137 mM NaI instead of NaCl) was added to each well. The fluorescence signal was measured
for a further 14 seconds with a sampling rate of 200 milliseconds. The resulting fluorescent
intensity was then normalized to the readings prior to injection of iodide solution and expo-
nential curve fitted to the data to calculate the rate of iodide flux.
Statistical analysis
Statistical analysis on data presented in this study was performed using Kruskal-Wallis with
Dunn’s multiple comparison test. Statistical significance was indicated by p<0.05.
Results
Confirmation of adenovirus transduction efficiency and cytotoxicity in
pAECCF
Initial assessment of transduction efficiency by the adenoviral vector in CF primary AEC was
required to ascertain that these cells were suitable for assay development. A series of transduc-
tions of pAECCF with different MOI of the adenoviral vector followed by semi-quantitative
measurement of eYFP-expressing cells demonstrated that the fluorescent signal intensified
with increasing titres of eYFP-encoding adenovirus (Fig 1). Very high transfection efficiency
(85.01±1.45%) was achieved at the minimum MOI 500 and there appeared to be no significant
cytotoxic effect, as cells retained their typical epithelial morphology. This was confirmed by
measuring LDH production and cell viability post transduction which showed no significant
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Fig 1. Assessment of transduction efficiency in primary airway epithelial cells from children with CF. Primary AECs from
children with CF were seeded into 96-well culture plates, grown to confluence and transduced with adenoviral construct carrying
Halide assay to assess CFTR function restoration
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difference between untransduced cells and those transduced with different MOI of YFP (Fig
1B and 1C). The expression of eYFP was maintained for the duration of the intended halide
assay of 96 hours. Thus, for all subsequent experiments, eYFP at the lowest MOI 500 was used
to transduce the pAEC.
Assessment of transduction by adenoviral constructs in pAECCF
The next step was to assess transduction of eYFP in combination with transduction by positive
shRNA control to determine whether eYFP expression was altered when cells were transduced
with more than one construct. Positive controls assessed were WT-CFTR cDNA, as well as
shRNA targeting STX8 or BCAP-31, two factors that regulate CFTR trafficking and prevent
intracellular migration of defective p.Phe508del CFTR to the plasma membrane [23,24]. Fig 2
represents a series of panels of bright field and fluorescence photomicrographs of pAECCF in a
representative control (non-transduced) sample, eYFP alone, or eYFP in combination with
WT-CFTR cDNA, BCAP-31 shRNA or STX8 shRNA. In each setting except the BCAP-31
panel, cells retained their morphology following transduction with minimal cytotoxicity.
When transduced with BCAP-31 and eYFP, cells appeared smaller and stressed as indicated by
the presence of numerous intracellular vacuoles. Assessment of cell cytotoxicity via LDH
release demonstrated no significant cytotoxicity following transduction with eYFP alone or in
combination with WT-CFTR, STX8 or BCAP-31. We again quantified the number of eYFP
positive cells and found that co-transduction of primary CF AECs with any of the positive con-
trol constructs still retained greater than 85% efficiency.
Determination of optimal output parameters
Having determined that pAECCF can be successfully and efficiently transduced to express
eYFP without any significant cytotoxic effect, a series of experiments were conducted to assess
the optimal output parameters. Post-transduction with eYFP alone, cells were placed into the
POLARStar plate reader and the assay performed with fluorescence outputs measured from
either top or bottom of the plate. Because no positive controls were applied and p.Phe508del
homozygous pAEC have minimal CFTR function, little to no change in fluorescence was
expected to occur. Top reading of fluorescence demonstrated spontaneous peaks at the time of
iodide injection and that this occurred independent of whether the cells were transduced or
not at any MOI. These peaks possibly represented reading artefacts due to the fluid injection
scattering light and may act to confound data during analysis (Fig 3A). In contrast, there were
fewer instabilities on the bottom reading which provided more stable and consistent data
(Fig 3B).
Discriminating CFTR restoration due to improved trafficking
Restoration of p.Phe508del CFTR function can be achieved by overcoming the poor trafficking
of the mutated CFTR. Here, the ability of the halide assay to discriminate restoration was first
assessed in cells transduced with eYFP and either STX8 or BCAP-31 shRNA to inhibit their
eYFP at a range of MOI (500, 1000 and 2000) over 48 hours. (A) Control non-transduced cells exhibited a typical cobblestone
morphology and lacked any fluorescence. Following infection at MOI 500, 1000 and 2000, pAECCF displayed a high transduction
efficiency with a majority of cells expressing eYFP. Signal intensity appeared to correlate with increasing MOI with little cytopathic
effect. When quantified, more than 85% of cells were found to express eYFP, and that this increased with MOI. (Representative
photomicrographs taken using 4x objective magnification from experiments conducted on 3 separate subjects) (B) Cell cytotoxicity as
measured by LDH production was negligible over all MOI transduction parameters with eYFP and until the completion of the halide
assay (n = 4). (C) No significant effect on cell viability was observed over the assay period (n = 4). Dash line indicates untransduced
cells.
https://doi.org/10.1371/journal.pone.0191618.g001
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Fig 2. Confirmation of successful transduction of positive controls and WT-CFTR in CF cells. (A) Primary AEC from children with CF were seeded
into 96-well culture plates and maintained in culture until confluent. Cells were then transduced with adenoviral constructs containing eYFP alone or in
combination with wild-type CFTR (WT-CFTR), or BCAP-31 or STX-8 shRNA vectors for 96 hours after which fluorescence micrographs were taken.
Results showed minimal auto fluorescence in non-transduced cells, whilst fluorescent signals were detected following transduction with all other
constructs. Quantification revealed that greater than 85% of cells expressed eYFP following transduction with any particular construct. (Representative
photomicrographs taken using 4x objective magnification from experiments conducted on 4 separate subjects) (B) Assessment of LDH release
demonstrated minimal cytotoxicity associated with transduction of pAECs with eYFP alone or in combination with WT-CFTR, STX8 or BCAP-31(n = 4).
https://doi.org/10.1371/journal.pone.0191618.g002
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production. It was evident that knockdown of either STX8 or BCAP-31 resulted in the rescue
of defective CFTR channels in pAECCF as indicated by the fluorescent quenching (Fig 4A).
Therefore, both STX8 and BCAP-31 were used as positive controls in all subsequent
experiments.
It has also been previously demonstrated that defective p.Phe508del CFTR channel traffick-
ing can be rescued by culturing cells at lower temperatures [25]. We performed a similar
assessment by transducing cells with both eYFP and p.Phe508del cDNA, before incubation at
27˚C for 24 hours prior to performing the halide assay. Quenching of the eYFP fluorescent sig-
nal was observed (Fig 4B), indicating increased levels of p.Phe508del CFTR were achieved at
the cell surface. Overall, data obtained from the transduction with three different positive con-
trols and the recognized temperature rescue method suggest the halide assay is able to discrim-
inate CFTR restoration in pAECCF homozygous for the p.Phe508del mutation.
Inter-subject performance of halide reporter assay
Once the halide assay was established in our primary cell model, a total of 7 pAECCF cultures
were setup to confirm maximal restoration of CFTR function by transduction with WT-CFTR.
Positive controls STX8 and BCAP-31 were also included to assess their capacity for channel
restoration compared to WT-CFTR. Fig 5A illustrates representative halide assay readouts
from three separate children homozygous for the p.Phe508del mutation. Graphs illustrated the
minimum-maximum inter-subject variability in output readings with the lowest (A-top
Fig 3. Optimization of output readings from different depths of the culture well. Primary AECs from children with
CF were seeded into 96-well culture plates, grown to confluence and transduced with eYFP at MOI 500 for 96 hours.
Iodide solution was then injected into each well and eYFP fluorescence then read either from the apical (top) or basal
(bottom) location of each well. (A) Analysis revealed that top readings resulted in instabilities of fluorescent signal that
coincided with the time of iodide injection. Furthermore, there was also inconsistency in the fluorescence signal
readouts independent of whether the cells were transduced or not. (B) In contrast, bottom reading outputs were more
stable and consistent, with no instabilities in fluorescent signal intensity. Therefore, all subsequent halide assay
measurements were taken from the bottom of the well.
https://doi.org/10.1371/journal.pone.0191618.g003
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panel), average (middle) and highest level of halide flux (bottom) respectively of the seven sub-
jects assessed. Analysis of pooled data from all subjects demonstrated that transduction with
eYFP alone resulted in minimal halide flux (Fig 5B). However, transduction with WT-CFTR
or STX8 shRNA resulted in a significant reduction of eYFP fluorescence post-iodide injection,
indicating restoration of CFTR function had occurred (p<0.05). Overall, eYFP fluorescence
values decreased approximately 15.2 ± 6.29% in response to WT-CFTR transduction, and
about 15.7 ± 8.69% post STX8 shRNA. Meanwhile, transduction with BCAP-31 shRNA
resulted only in lower quenching of eYFP fluorescence signals (7.49 ± 8.04%).
Discussion
In this study, we assessed the potential of using a halide reporter assay based around an
enhanced eYFP molecule to determine functional CFTR correction in pediatric pAEC from
children with CF. Firstly, it was confirmed that pAECCF could be transduced with high effi-
ciency using an adenoviral construct carrying the eYFP gene, with a positive relationship
between transduction efficiency and MOI of the construct used. Our findings also suggested
minimal cytotoxicity in pAECCF following transduction with eYFP alone or in combination
with WT-CFTR or STX8, with BCAP-31 shRNA appearing to induce some level of cellular
stress. Evaluation of different approaches to assay readouts verified that measuring eYFP fluo-
rescence from the bottom of the microplate resulted in minimal signal instabilities. In contrast,
reading the plate from the top resulted in spontaneous peaks at the time of iodide injection,
independent of any adenoviral construct being added, which would confound data during
analysis.
Fig 4. Assessment of adenoviral constructs and CFTR functional restoration using low temperature rescue. (A)
Primary AEC from children with CF were seeded into 96-well plates, grown to confluence and transduced with eYFP
alone or in combination with positive controls STX-8 or BCAP-31 shRNA for 96 hours prior to performing the
reporter assay. Knock-down of STX8 or BCAP-31 resulted in functional CFTR indicated by quenching of eYFP
fluorescence signals. (B) Following transduction of pAECCF with eYFP and p.Phe508del cells were returned to 37˚C
incubator for 72 hours, followed by incubation at 27˚C for 24 hours prior to halide assay. Halide assay demonstrated
activation of the CFTR channels resulting in quenching of the eYFP fluorescence signal. This indicates the feasibility of
using halide assay as a tool to measure functional restoration of CFTR channel.
https://doi.org/10.1371/journal.pone.0191618.g004
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Minimal or no reduction in eYFP fluorescence readouts occurred for pAECCF that were
transduced with eYFP only. Whereas, transduction with eYFP in combination with WT-CFTR
or either of the positive controls did result in fluorescence quenching, indicating increased
CFTR function had been achieved and these were corroborated by separate assays performed
after low temperature rescue of p.Phe508del CFTR channel trafficking. Inter-subject variability
in output readings are most likely reflective of the inherent phenotypic variance in human CF
populations, even within homozygous mutation genotypes. This further highlights the need
for individual-based analysis of any potential therapy and is the subject of a study by our
group with particular implications for personalized high-throughput screening of CFTR thera-
peutics across all phenotypic classes of CFTR function.
The gold standard method of measuring ion transport via Ussing chamber provides a more
accurate functional assessment of the CFTR channel. However, this method requires cells
grown at air-liquid interface, which can often take up to 28 days before any assessment is per-
formed, thus limiting the feasibility of this method as a high-throughput screen. In contrast,
the halide assay can be adapted into various small-scale, high-throughput platforms using
either 96- or 384-well plate formats for the rapid assessment of CFTR functionality. Mini-
aturization combined with the use of patient derived AEC, which provides reflection on the
phenotypic variance within the CF population, can then be adapted for a more personalized
approach for CF therapy to cater especially for individuals with rare CFTR mutations. How-
ever, the main limitation to this method is in using a submerged culture format, which is often
not reflective of the differentiated airways in vivo. Nonetheless, the halide assay is highly adapt-
able and ideal for the rapid screening of therapeutic compounds targeting specific CFTR muta-
tions. Results generated by this assay can be subsequently verified using Ussing to corroborate
activity in a differentiated airway setting.
This study explored an alternative halide assay first developed by Verkman [7], where a
halide ion was used to quench a reporter gene expression that is co-expressed with the
WT-CFTR gene. Most high throughput screening studies using fluorescent techniques to eval-
uate compounds for CFTR corrective capabilities have utilized Swiss 3T3 mouse fibroblasts
[26,27] or Fischer rat thyroid cells [22,28,29] that were then stably transfected to express p.
Phe508del. Other studies have either used human bronchial cell lines such as CFBE41o- [29]
or cultures of human bronchial epithelial cells established from lung resections or transplant
tissues for confirmation studies of CFTR expression and function [27,30]. However, the use of
immortalized cell lines including those that were virally transformed may not always reflect
characteristics of primary airway epithelial cells and individual patient responses to different
therapeutic compounds cannot be captured when generic cell lines or animal cells are used as
part of a HTS platform. Recent studies on CFTR rescue have been performed using AECs iso-
lated from bronchial tissues following biopsy or lung transplantation in adults [31–34]. How-
ever, it is known that the lung environment and subsequent disease pathogenesis greatly differ
between children and adults and there remains paucity of data on the assessment of CFTR
channel functionality using AECs from pediatric populations. Significantly, this study using
Fig 5. Confirmation of CFTR channel functional restoration in pAECCF. (A) A representative of three separate halide assays
on pAECCF cultures illustrating the lowest (top panel), average (middle panel) and highest (bottom panel) level of halide influx.
Epithelial cell cultures from a total of 7 children with CF were seeded into 96-well culture plates and transduced with eYFP
alone or in combination with STX-8, BCAP-31 shRNA or WT-CFTR for 96 hours. The halide reporter assay was then
performed and data analyzed from all 7 cultures to determine the relative quenching of eYFP fluorescence. (B) Analysis of data
demonstrated that transduction with constructs bearing shRNA for STX-8 or WT-CFTR activated the CFTR channel resulting
in subsequent eYFP quenching. This further verified functional restoration of the CFTR channel. However, transduction with
construct bearing shRNA for BCAP-31 only resulted in low quenching of eYFP. NOTE:  denotes significant difference at
p<0.05.
https://doi.org/10.1371/journal.pone.0191618.g005
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pAECCF overcomes these limitations and thus advances the field of CFTR assessment by mak-
ing personalized high-throughput screening a reality. Furthermore, the use of cell cultures
from a pediatric population, as in this study, illustrates the potential of this screening platform
in early life interventional therapy.
There have been significant advances in the development of small molecules to target the
defective CFTR at molecular level with promising results [35]. Two of these molecules, the
CFTR potentiator ivacaftor and the CFTR corrector lumacaftor have been recently approved
for therapeutic use in several countries. However, due to the many mutations of the CFTR
gene, there are ongoing investigations for additional CFTR modulators to correct rarer or
functionally unique CFTR mutations. These investigations would be significantly benefitted
by a high-throughput screening platform that could assess CFTR functional restoration in a
scale that uses fewer cells and over a shorter period.
Other methods that have been used to measure CFTR function in vitro include the fluores-
cence-resonance energy transfer (FRET)-based assay [31] and fluorescent membrane potential
probe in FlexStation-based membrane potential assay [36,37]. Despite the widespread use of
FRET-based assay technology for high-throughput ion channel drug discovery, there remains
significant limitations including low signal to noise ratio as well specific requirements pertain-
ing to the physical properties of the fluorescence labels in order for the assay’s accuracy [38].
Encouragingly, with improved technologies and new innovations, these limitations are pro-
gressively being overcome. The fluorescent membrane potential probe assay provides further
advancement in the monitoring of CFTR function with it ease of use. However, the assay was
initially optimized in cell lines manipulated to highly express CFTR and has only very recently
been translated to patient derived samples. Further validation will be required, specifically in a
very young pediatric cohort.
Here, we have provided proof of concept of a small-scale halide assay using primary pediat-
ric airway cultures for assessing CFTR restoration. This small scale assay could be further
adapted for a high-throughput screening format to allow for personalized (individual patient-
specific) assessment of CFTR correction using an existing and/or novel compound(s). This
assay can then be setup either for personalized screening of multiple compounds or for testing
a specific compound for a range of CFTR mutations. Moreover, any prospective therapy can
be assessed in adult-derived airway epithelial cells to determine its potential benefit over age
and disease progression.
The benefits of using halide-sensitive fluorescent reporter include capacity to miniaturize
the format to 384-well, the ability to measure heterogeneous CFTR combinations and an
apparent high sensitivity of detection for functional CFTR expression [8]. Notwithstanding the
benefits of using pediatric primary cultures, these cultures also have their limitations. Cells
could be only be passaged up to 5 times before reaching terminal expansion potential under
traditional culturing approaches [19]. A new method using of Rho-associated protein kinase
(ROCK) inhibitor in combination with mitotically-inactive fibroblast feeder layers could be
adapted to overcome this challenge [39]. A recent study demonstrated that applying such a
combination in endotracheal-derived cells increased their growth rate and also produced func-
tional airway epithelial cells for various applications [40]. Despite the potential of this method,
it remains relatively new and we are currently validating the halide assay under these culture
conditions for comparison to unmodified pAECCF cultures.
Recently, other studies have used methods including three-dimensional organoids and
induced pluripotent stem cells (iPSC) to assess CFTR function in patient-specific settings
[17,40–44]. The study by Dekkers et al. used an intestinal organoid system to study CFTR
function in such a personalized setting [17]. In healthy-derived organoids, application of the
CFTR stimulant forskolin caused swelling of the sphere’s size, reflecting normal CFTR
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function, whilst the same degree of swelling was not observed in CF-derived organoids. Orga-
noids were also previously used by Schwank et al. to study functional repair of CFTR by
CRISPR/Cas9 editing system [41]. They observed swelling in the corrected organoids follow-
ing administration of forskolin, whereas no swelling was detected in control uncorrected orga-
noids. Despite promising findings, differences between the low turnover of airway cells
compared to the intestine, the low CFTR expression that might affect the rate of forskolin-
induced swelling, and the possible presence of compensatory non-CFTR channels [45] all
raises queries to their appropriateness as an airway surrogate. Excitingly, recent work by two
groups have reported the successful formation of airway organoids and their potential applica-
tion for HTS [46,47]. Even with these advancements, organoid modelling remains relatively
new and additional research on its relevance to assess CFTR function that reflect/mimic in
vivo conditions is required.
Another field that has gained momentum in recent years is the use of iPSC-derived cell cul-
tures as they can be differentiated into a variety of tissue-specific cell types including airway
epithelium [42–44]. Firth et al. successfully demonstrated differentiation of human iPSC into
polarized airway epithelium with ciliated cells and functional CFTR activity [42]. As iPSCs can
be generated from a blood sample in patient-specific settings, this model has attracted a lot of
interest as an unlimited source of patient-specific airway epithelial cells. Despite the potential,
induction of iPSC into airway epithelium is typically laborious and involves multiple, meticu-
lous steps to ensure the production of appropriate cues that allow cells to follow desired line-
ages. Challenges regarding the need for homogeneous cell population with no contamination
by undifferentiated cells and the cost and complexity of the technique all suggest that this
model system still requires considerable refinement.
Conclusions
This study has demonstrated that the eYFP-halide reporter assay is an efficient technique to
evaluate successfully restored and activated p.Phe508del in CF primary airway epithelial cells.
More importantly, due to its small-scaled format, the use of patient-specific primary airway
cells and the reporter readout, this assay may have potential as a personalized HTS tool to
screen and identify the most optimal therapy for particular individuals with CF are amenable
to, irrespective of the mutation causing the disease.
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